Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allos reports progress with brain tumor drug study
The phase III study is designed to evaluate the safety and efficacy of whole brain radiation therapy with increased oxygen. Efaproxyn increases the amount of oxygen in tumors
The phase III study is designed to evaluate the safety and efficacy of whole brain radiation therapy with increased oxygen. Efaproxyn increases the amount of oxygen in tumors
AzaSite is designed to treat bacterial conjunctivitis by enhancing the time the antibiotic spends on the surface of the eye. The application included clinical trials in which 698
The trial, named Study 07, was a randomized, double-blind, placebo-controlled study. The primary endpoint was the proportion of patients with at least a 50% improvement in the Brief
Financial terms of the transaction were not disclosed. However, Boehringer Ingelheim did reveal that IdeaSphere will take over the Pharmaton business and brands in their entirety. Both companies
BrainStorm, which focuses on treatments for neurodegenerative diseases, has previously demonstrated that its bone marrow stem cell technology can successfully differentiate adult stem cells into astrocyte-like cells with
If approved, guanfacine extended release (previously referred to as SPD503) would be the first once-daily selective alpha-2A-adrenoceptor agonist for the treatment of ADHD in children aged six to
The alliance aims to focus on novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders, including Traficet-EN, which is in
Bioxel’s paclitaxel active pharmaceutical ingredient (API) will be used by its client, which remains undisclosed, in generic drug product marketed primarily in Europe. This first order is valued
PXD101 will be evaluated in patients whose previous treatment regimen did not work or whose cancer returned after treatment. The trial, also known as S0520, is sponsored by
The rolling biologics license application (BLA) submission is seeking clearance to market Provenge (sipuleucel-T) for the treatment of asymptomatic patients with metastatic, androgen-independent (also known as hormone-refractory) prostate